This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Gilead (GILD) Exercises Options to Three Arcus Programs
by Zacks Equity Research
Gilead (GILD) exercises options to Arcus' anti-TIGIT Program (domvanalimab and AB308), etrumadenant (A2a/A2b Adenosine Receptor Antagonist), and quemliclustat (small Molecule CD73 Inhibitor).
Gilead (GILD), Everest Medicine Report Phase II Cancer Study Data (Revised)
by Zacks Equity Research
Gilead (GLD) and partner Everest Medicine report that the mid-stage study of sacituzumab govitecan for triple-negative breast cancer achieved its main goal.
Gilead (GILD), Everest Medicine Report Phase II Cancer Study Data
by Zacks Equity Research
Gilead (GLD) and partner Everest Medicine report that the mid-stage study of sacituzumab govitecan for triple-negative breast cancer achieved its main goal.
Ligand (LGND) Beats on Q3 Earnings, Plans to Separate OmniAb
by Zacks Equity Research
Ligand (LGND) reports encouraging third-quarter 2021 numbers by beating estimates on both counts.
How Are Biotech ETFs Reacting to These Q3 Earnings Releases?
by Sweta Jaiswal, FRM
Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.
FATE's Q3 Loss Narrower Than Expected, Pipeline in Focus
by Zacks Equity Research
FATE reports a year-over-year wider loss on increased R&D expenses in the third quarter.
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for IBB
Intercept (ICPT) Beats on Q3 Earnings & Sales, Ups View
by Zacks Equity Research
Intercept (ICPT) posts a narrower loss in the third quarter and sales beat estimates.
Gilead (GILD) Q3 Earnings Beat on Increased Veklury Sales
by Zacks Equity Research
Gilead (GILD) beats on sales and earnings in the third quarter. While the HIV business is affected by the pandemic and generics, Veklury maintains momentum.
Markets Close at or Near Record Highs; Sales Misses for AAPL, AMZN, SBUX
by Mark Vickery
Most of these economic metrics and earnings reports are a peek in the rearview mirror; the real news is ahead of us.
Gilead Sciences (GILD) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Gilead (GILD) delivered earnings and revenue surprises of 54.07% and 19.16%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Higher Jakafi Sales Boost Incyte's (INCY) Q3 Earnings?
by Zacks Equity Research
Incyte's (INCY) third-quarter 2021 earnings are likely to have gained from higher Jakafi sales as patients resume visits to the doctors.
Healthcare ETFs in Focus as Q3 Earnings Unfold
by Sweta Killa
The healthcare sector is expected to witness substantial earnings growth of 17.5% in the third quarter.
Biotech Stock Roundup: BMY's Q3 Earnings Beat, MRNA's Vaccine Updates & More
by Zacks Equity Research
Earnings and other updates from bigwigs like Bristol Myers (BMY) and Moderna (MRNA) have been the biotech sector's few key highlights during the past week.
Why Gilead (GILD) Might Surprise This Earnings Season
by Zacks Equity Research
Gilead (GILD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Should You Invest in the iShares Biotechnology ETF (IBB)?
by Zacks Equity Research
Sector ETF report for IBB
Should You Invest in the Invesco Dynamic Pharmaceuticals ETF (PJP)?
by Zacks Equity Research
Sector ETF report for PJP
Gilead (GILD) to Report Q3 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
Investors will focus on the HIV franchise's performance and Veklury sales in Gilead's (GILD) third-quarter 2021 results.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed the most recent trading day at $67.24, moving +0.37% from the previous trading session.
What is in Store for Bristol-Myers (BMY) in Q3 Earnings?
by Zacks Equity Research
Bristol-Myers' (BMY) Q3 earnings might have gained from strong demand for its multiple myeloma drug, Revlimid. Operating expenses might have jumped due to costs associated with the broader portfolio.
Gilead Sciences (GILD) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biotech Stock Roundup: BIIB's Q3 Earnings, REGN's COVID-19 Cocktail Update & More
by Zacks Equity Research
Regulatory and pipeline updates from bigwigs like Regeneron (REGN) and Biogen (BIIB) have been the biotech sector's few key highlights during the past week.
Gilead's (GILD) Biktarvy Gets FDA Nod for Pediatric Patients
by Zacks Equity Research
Gilead (GILD) wins FDA approval for the label expansion of HIV treatment Biktarvy for the pediatric patient population.
Biogen (BIIB) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on sales of new Alzheimer's drug, Aduhelm when Biogen (BIIB) reports third-quarter earnings.